Phase 3 N=361 The TRANQUILITY 2 Trial: A Phase 3 Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease
Dry Eye
Primary: Schirmer Test Mean Change From Baseline — 1.8; -0.5 length in millimeters
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=1 StrataGraft Safety, Tolerability and Efficacy in Pediatric Subjects
Skin Wound · Burns · Trauma-related Wound
Primary: Percentage of Participants Who Achieved Confirmed Complete Closure of StrataGraft Treatment Sites Without Autograft Within 12 Weeks of StrataGraft Application — 100…
Phase 2 N=83 Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects
Urothelial Carcinoma · Bladder Cancer
Primary: Phase Ib: Safety of Pembrolizumab in Combination With Gemcitabine-Cisplatin — 0 Participants
Phase 2 N=83 Safety and Efficacy of HB-1 for Panic Disorder
Panic Disorder
Primary: Incidence of Treatment-Emergent Adverse Events — 23; 15 Participants
Phase 2 N=83 Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma
Plasma Cell Leukemia · Plasmacytoma · Recurrent Plasma Cell Myeloma
Primary: Progression Free Survival (PFS) — 38; 24 Participants
N/A N=310 Mobile Apps to Reduce Distress in Breast Cancer Survivors Using an Adaptive Design
Depression, Anxiety · Engagement, Patient
Primary: Patient Health Questionnaire-8 — 12.1; 11.8; 12.5; 12.7 score on a scale
N/A N=10,252 IMPROVE AKI Cluster-Randomized Trial
Acute Kidney Injury
Primary: Acute Kidney Injury — 110; 190; 122; 88 Participants
N/A N=31 Clinical Trial of the invisaRED® IR REHAB Device When Used as an Adjunctive Therapy for Nociceptive Musculoskeletal Pain
Nociceptive Pain · Musculoskeletal Pain
Primary: Measured Change in the Participants Pain Levels — 61.46; 19.79 Score on a scale — p=<0.01
N/A N=62 Dietary Supplement With and Without a Probiotic
Healthy Adult Subjects
Primary: Evaluation of the Levels of B.Infantis in Stool by Quantitative PCR — 3.33; 3.33; 3.33; 3.33 copies/ng DNA — p=<0.0001
N/A N=60 Post Market Study Evaluating Princess Filler Lidocaine for the Correction of Nasolabial Folds
Correction of Nasolabial Folds
Primary: Change From Baseline in Average Nasolabial Folds-Severity Rating Scale (NLF-SRS) Grade Based on Investigator Assessment at Week 24 — -1.8 score on a scale
N/A N=22 Perinatal Attentional Retraining Intervention for Smoking for Minority Women
Postpartum Smoking Relapse
Primary: Attentional Bias- Smoking Related Stimuli — -44.0; 37.9 milliseconds — p=>0.05
N/A N=25 Investigating Hearing Aid Frequency Response Curves 2
Hearing Loss, Sensorineural · Hearing Loss, Bilateral
Primary: Sound Quality Ratings - Listening Comfort - Program 1 — 4.78; 6.04; 2.36 Mean Preference Counts per Participant — p=<0.001
N/A N=132 Brief Intervention for Justice-Involved Substance Users
Substance Use · Violence
Primary: Percent Days Abstinent — 44; 42 percentage of days abstinent — p=.07
N/A N=299 Healthy Lifestyle Intervention for High-Risk Minority Pregnant Women
Emotional Disturbances · Depression · Pregnancy Late
Primary: Change in Self-reported Healthy Lifestyle Beliefs Timepoint 0 to Timepoint 3 — 59.044; 59.349; 64.972; 64.234 units on a scale — p=<0.001
Phase 3 N=583 Negative Pressure Wound Therapy in Post-Operative Incision Management
Negative-Pressure Wound Therapy
Primary: Number of Post-op Wound Complications — 2; 5; 42; 36 Wound Complications